Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bendamustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 7/20 | 0.96 |
| ▸ | HDAC1 known ✓ | Q13547 | 4/20 | 0.96 |
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.96 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.96 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.96 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.96 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 2/20 | 0.96 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.96 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.96 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.50 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendamustine SCHEMBL15523734 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29352819 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL18843 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL12497247 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL26319 | 0.98 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 0.98 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29394147 | 0.98 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15436003 | 0.96 | HDAC6 (0.96) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL2783279 | 0.95 | HDAC6 (0.90) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16772708 | 0.95 | HDAC6 (0.94) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390331-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2024-11-28 | — | — | US | claimed |
| EP-4419147-A1 | LIQUID PHARMACEUTICAL FORMULATION | Project Pharmaceutics GmbH (DE) | 2024-08-28 | — | — | EP | claimed |
| CN-118541168-A | Liquid pharmaceutical formulation | 项目制药股份有限公司 | 2024-08-23 | — | — | CN | claimed |
| US-11826466-B2 | Bendamustine solution formulations | NAVINTA, LLC (US) | 2023-11-28 | — | — | US | claimed |
| WO-2023067188-A1 | LIQUID PHARMACEUTICAL FORMULATION | PROJECT PHARMACEUTICS GMBH (DE) | 2023-04-27 | — | — | WO | claimed |
| US-20210169798-A1 | Bendamustine Solution Formulations | PROVIDENT BANK | 2021-06-10 | — | — | US | claimed |
| EP-3691637-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE Pharmaceuticals GmbH (AT) | 2020-08-12 | — | — | EP | claimed |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2020-08-06 | — | — | US | claimed |
| CN-111201019-A | Oral bendamustine formulations | 图贝药物有限公司 | 2020-05-26 | — | — | CN | claimed |
| WO-2019068904-A1 | ORAL BENDAMUSTINE FORMULATIONS | TUBE PHARMACEUTICALS GMBH (AT) | 2019-04-11 | — | — | WO | claimed |
| EP-2970144-A1 | PROCESS FOR DRYING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE | Johnson Matthey Public Limited Company (GB) | 2016-01-20 | — | — | EP | claimed |
| US-20150175554-A1 | Highly pure bendamustine hydrochloride monohydrate | SHILPA MEDICARE LTD (IN) | 2015-06-25 | — | — | US | claimed |
| US-20150051258-A1 | Novel Solid Forms Of Bendamustine Hydrochloride | CEPHALON INC (US) | 2015-02-19 | — | — | US | claimed |
| WO-2014170769-A2 | BENDAMUSTINE LYOPHILIZED PHARMACEUTICAL COMPOSITIONS | SHILPA MEDICARE LIMITED (IN) | 2014-10-23 | — | — | WO | claimed |
| US-20140275566-A1 | PROCESS FOR DRYING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE | JOHNSON MATTHEY PLC (GB) | 2014-09-18 | — | — | US | claimed |
| WO-2014140929-A1 | PROCESS FOR DRYING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-09-18 | — | — | WO | claimed |
| EP-2635558-A1 | PROCESS FOR PREPARING BENDAMUS TINE HYDROCHLORIDE MONOHYDRATE | Shilpa Medicare Limited (IN) | 2013-09-11 | — | — | EP | claimed |
| US-20130217888-A1 | PROCESS FOR PREPARING BENDAMUS TINE HYDROCHLORIDE MONOHYDRATE | SHAILPA MEDICARE LIMITED (IN) | 2013-08-22 | — | — | US | claimed |
| WO-2012059935-A9 | PROCESS FOR PREPARING BENDAMUS TINE HYDROCHLORIDE MONOHYDRATE | SHILPA MEDICARE LIMITED (IN) | 2012-06-14 | — | — | WO | claimed |
| WO-2012059935-A1 | PROCESS FOR PREPARING BENDAMUS TINE HYDROCHLORIDE MONOHYDRATE | SHILPA MEDICARE LIMITED (IN) | 2012-05-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051258-A1 | Novel Solid Forms Of Bendamustine Hydrochloride | FLT3, FOLR1, FOLR2 | HDAC6 1183/4885HDAC1 3058/4885HDAC3 3452/4885 |
| US-11826466-B2 | Bendamustine solution formulations | BHMT, BHMT2, BAD | HDAC6 1244/4885HDAC1 1909/4885HDAC3 3451/4885 |
| US-20200246312-A1 | ORAL BENDAMUSTINE FORMULATIONS | ABCB1, MTHFD1, BHMT | HDAC6 851/4885HDAC1 2357/4885HDAC3 2653/4885 |
| US-20130217888-A1 | PROCESS FOR PREPARING BENDAMUS TINE HYDROCHLORIDE MONOHYDRATE | FLT3, TYMP, SBDS | HDAC6 3562/4885HDAC1 4483/4885HDAC3 4762/4885 |
| US-20210169798-A1 | Bendamustine Solution Formulations | BHMT, BHMT2, BAD | HDAC6 1244/4885HDAC1 1909/4885HDAC3 3451/4885 |
| US-20150175554-A1 | Highly pure bendamustine hydrochloride monohydrate | BHMT, FOLR2, SMCHD1 | HDAC6 3846/4885HDAC1 4015/4885HDAC3 4728/4885 |
| US-20240390331-A1 | ORAL BENDAMUSTINE FORMULATIONS | BHMT, MTHFD1, ABCB1 | HDAC6 795/4885HDAC1 2182/4885HDAC3 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.